# Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance), Division: Laboratory criteria for case confirmation

Extent: E+W+S+N.I.

At least one of the following three:
Isolation of virus in cell culture from any clinical specimen and identification of SARS-CoV using method such as RT-PCR
Detection SARS-CoV nucleic acid in at least one of the following three:
At least two different clinical specimens (for example, nasopharyngeal swab and stool)
The same clinical specimen collected on two or more occasions during the course of the illness (for example, sequential nasopharyngeal aspirates)
Two different assays or repeat RT-PCR using a new RNA extract from the original clinical sample on each occasion of testing
SARS-CoV specific antibody response by one of the following two:
Seroconversion by ELISA or IFA in acute and convalescent phase serum tested in parallel
Four-fold or greater rise in antibody titre between acute and convalescent phase sera tested in parallel

---
Source: https://www.legislation.gov.uk/eudn/2018/945/annex/II/division/3/division/3.39/division/2/division/1 (the official version)
Page: https://openlegislation.uk/eu-decision-2018-945/annex-II/division-3/division-3.39/division-2/division-1
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.